Dr Reddys Laboratories (RDY) EPS (Basic) (2009 - 2023)

Dr Reddys Laboratories (RDY) posted quarterly EPS (Basic) of $0.21 for Q2 2023, up 5.33% quarter-over-quarter from $0.2 in Q1 2023.

Dr Reddys Laboratories (RDY) EPS (Basic) (2009 - 2023) Analysis & Trends

Dr Reddys Laboratories' EPS (Basic) history runs 15 years deep, the most recent figure standing at $0.21 for Q2 2023.

In Q2 2023, EPS (Basic) changed N/A year-over-year to $0.21; the TTM figure through Mar 2026 stood at $0.21 (down 48.67% YoY), while the FY2026 annual figure was $0.55, down 31.18% from the prior year.
EPS (Basic) for Q2 2023 stood at $0.21, up from $0.2 in the prior quarter.
The five-year high for EPS (Basic) was $0.21 in Q2 2023, with the low at -$0.13 in Q3 2020.
The 5-year median for EPS (Basic) is $0.13 (2022), against an average of $0.1.
Peak annual rise in EPS (Basic) reached 121.65% in 2019, while the deepest fall reached 214.24% in 2019.
Dr Reddys Laboratories' EPS (Basic) stood at -$0.1 in 2019, then tumbled by 35.13% to -$0.13 in 2020, then surged by 224.01% to $0.16 in 2021, then slipped by 12.71% to $0.14 in 2022, then surged by 52.0% to $0.21 in 2023.
Business Quant data shows RDY's EPS (Basic) at $0.21 in Q2 2023, $0.2 in Q1 2023, and $0.14 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Haleon	43.91 Bn	42.95 Bn	-	-
2	Teva Pharmaceutical Industries	43.07 Bn	39.42 Bn	2.15 Bn	-0.49
3	Zoetis	31.54 Bn	29.86 Bn	1.05 Bn	2.07
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	0.45
5	United Therapeutics	22.19 Bn	19.53 Bn	683.80 Mn	7.82
6	Viatris	18.68 Bn	17.79 Bn	1.46 Bn	-0.10
7	Neurocrine Biosciences	15.50 Bn	15.11 Bn	935.80 Mn	1.43
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn	0.11
9	Dr Reddys Laboratories	10.12 Bn	9.96 Bn	-	-
10	Alkermes	8.12 Bn	7.46 Bn	397.90 Mn	0.00

Download Data